Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC is a phase 2, interventional study registered as NCT06168786 by Huazhong University of Science and Technology, with a registry enrolment figure of 40 participants, started 2023-06-20 and due to reach its primary completion in 2026-02-28. Interventions recorded: Fruquintinib; Cadonilimab; SBRT. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.